Search results
Results from the WOW.Com Content Network
Natalizumab, sold under the brand name Tysabri among others, is a medication used to treat multiple sclerosis and Crohn's disease. [9] It is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin . [ 9 ]
Previously named Antegren, natalizumab is a drug co-marketed by Biogen Idec and Élan as "Tysabri". Tysabri is a monoclonal antibody that inhibits immune cells from crossing blood vessel walls to reach various tissues, including the brain.
New TYSABRI ® Data Show Earlier Treatment and Longer-Term Use Result in Significant Reductions in MS Disease Activity - Earlier Treatment with TYSABRI Demonstrated Reduction in Relapse Severity ...
In February 2013, Bloomberg broke the news that Biogen was planning to pay Elan $3.25 billion for the full rights to Tysabri, used to treat multiple sclerosis. [19] In 2013, Biogen was the first U.S.-based biotechnology company to appear on the Dow Jones Sustainability World Index. [20]
Tysabri is. Biotech firms Biogen Idec and Elan announced in a press statement released Wednesday that they have filed for regulatory approval to expand the use of multiple sclerosis drug Tysabri ...
Multiple sclerosis drug Tysabri is arguably the most important drug to both Biogen Idec (NAS: BIIB) and Elan (NYS: ELN) . It makes up essentially all Elan's sales after selling its drug- delivery ...
ADDING MULTIMEDIA New TYSABRI Data Reaffirm Substantial Efficacy in Treatment of People with MS and Demonstrate Stability of Anti-JCV Antibody Status - Continued Research into Risk Stratification ...
LifeArc humanised a number of antibodies on behalf of other organisations. Four of these, Tysabri (Biogen Idec/Elan), Actemra (Hoffmann-La Roche/Chugai), Entyvio (Millenium Pharma/Takeda) and Keytruda (Merck/MSD), are licensed drugs.